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Keputusan ujian jangkamasa yang berpanjangan di dalam ujian ‘activated partial throm-
boplastin time’ (APTT) dan jangka masa normal untuk ujian ‘prothrombin time’ (PT) adalah 
kemungkinan disebabkan samada kehadiran kepincangan dalam faktor pembekuan yang 
melibatkan faktor VIII, IX, XI atau XII, ataupun kehadiran penghalang pembekuan. Ke-
mungkinan penghalang pembekuan ini adalah spesifik terhadap sesuatu faktor pembe-
kuan atau ia adalah penghalang pembekuan tidak spesifik seperti ‘lupus anticoagulant’ 
yang memberi implikasi terapeutik yang tidak sehaluan. Kami melaporkan satu pesakit 
yang telah dirujuk kepada kami untuk rawatan dimana pendiagnosanya daripada hospital 
terdahulu melaporkan ia mempunyai penghalang faktor pembekuan IX dengan keabnor-
malan jangkamasa yang berpanjangan di dalam ujian APTT. Hasil lanjutan siasatan mak-
mal kami telah menunjukkan pesakit ini mempunyai penghalang pembekuan ‘lupus anti-
coagulant’ melalui ujian faktor ‘phospholipid-dependent’.  Ujian pencairan, ujian kromoge-
nik dan neutralisasi fosfolipid dapat membezakan penghalang pembekuan ‘lupus anticoa-
gulant’ dengan yang faktor pembekuan yang lain. Interpretasi terhadap ujian faktor dengan 
kehadiran penghalang pembekuan ‘lupus anticoagulant’ perlu dilakukan dengan berhati-
hati untuk mengelakkan diagnosis yang tidak tepat dan pemberian rawatan yang tidak se-
suai. 
 





The causes of an isolated prolonged activated partial thromboplastin time (APTT) with 
a normal prothrombin time (PT) are either a deficiency of clotting factors VIII, IX, XI or 
XII or the presence of an inhibitor. The inhibitor may be specific to an individual clotting 
factor or it may be a non-specific inhibitor like the lupus anticoagulant which has 
opposite therapeutic implications. We report a patient referred to our hospital for 
treatment that was previously diagnosed at another medical institution as an acquired 
factor IX inhibitor following an investigation for a prolonged APTT. On further testing 
this turned out to be a potent lupus anticoagulant which interfered with the 
phospholipid-dependent factor assays. The use of dilution studies, chromogenic 
assays and phospholipid neutralization can help differentiate these inhibitors. Great
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care must be taken in the interpretation of factor assays in the presence of lupus anti-
coagulant to avoid misdiagnosis and inappropriate treatment. 
 





Coagulation tests are usually requested 
by clinicians for a variety of reasons. It 
could be part of an investigation for a pa-
tient with bleeding tendencies or a rou-
tine test prior to a surgical procedure. 
With the increasing trend of routine coa-
gulation testing, the haemostasis labor-
atory is often burdened with the task of 
investigating an isolated prolonged 
APTT. In most cases, these turned out to 
be inconclusive or due to factor XII defi-
ciency which is of no clinical significance. 
In this case report we illustrate a patient 
with chronic myelomonocytic leukaemia 
who presented with multiple subcutane-
ous abscesses. The initial investigation 
showed a prolonged APTT, a low factor 
IX level and the presence of an inhibitor. 
She was diagnosed as an acquired factor 
IX inhibitor. On further testing this turned 
out to be a lupus anticoagulant. We dis-
cuss the investigation of a prolonged 
APTT and how to differentiate a specific 
factor inhibitor from a lupus anticoagu-
lant. This is the first case report that de-
monstrates correction of an apparent low 
factor level with phopholipid mixing stu-





A 51 year-old lady was diagnosed with 
chronic myelomonocytic leukaemia in 
August 2004 when she presented with 
epigastric pain and was noted to have an 
enlarged liver and spleen with monocyto-
sis. She remained well following treat-
ment with low dose cytarabine until three 
years later when she presented with mul-
tiple large abscesses over the buttocks, 
thigh and abdomen. She was seen by the 
orthopaedic surgeon and was planned for 
drainage and saucerisation of the ab-
scesses. She had no bleeding symp-
toms. Laboratory results included a hae-
moglobin of 10.4g/dL, a white blood cell 
count of 5.6x109/L, and a platelet count 
of 41x109/L. Prothrombin time was 12.2 
seconds (normal, 10.2-13.2 sec); APTT, 
72.2 seconds (normal, 21-32 sec) and 
fibrinogen, 362 mg/dL (normal 150-450 
mg/dL). Factor VIII:C activity was 72.9%; 
factor IX:C activity was 4.6%, with factor 
IX inhibitor of 4.0 Bethesda units (BU). In 
view of the results, she was diagnosed 
as having an acquired factor IX inhibitor. 
She was treated with recombinant acti-
vated factor VII at 90mcg/kg and under-
went the surgery without any bleeding or 
thrombotic complications. She was also 
given a course of antibiotics. However, 
three weeks later she returned with re-
currence of the abscesses in the left 
axilla and back. 
The patient was now referred to our 
hematology department for further man-
agement. She had no bleeding 
symptoms. A repeat coagulation test was 
done. The results showed PT was 14.7 
seconds (normal, 11.0-14.5 sec), APTT 
was 120.0 seconds (normal, 28-40 
seconds) and the mixing studies with 
normal plasma showed a persistent 
prolongation of the APTT at 96.5 seconds 
suggesting the presence of an inhibitor. 
Factor VIII:C was 22% (normal, 60%-
150%), factor IX:C was <1.0% (normal, 
60%-150%), factor XI was <1.0% and 
factor XII <1.0%. Serial dilutions for fac-
tor levels were assayed to look for speci-
ficity of the inhibitor (Table 1). A chromo-




genic factor VIII assay was also done 
and this showed a factor VIII level of 
120%. To demonstrate that the low factor 
levels were due to the presence of a 
lupus anticoagulant (LA), phospholipid 
was added to the factor assays. The 
factor levels rose confirming that the 
apparent low factor levels were due to 
the interference by the LA (Table 2). The 
platelet count was 80x109/L with the 
presence of giant platelets and platelet 
clumps. Further testing for LA was 
carried out. The dilute Russell’s viper 
venom test (DRVVT) was prolonged at 
88.2 seconds (normal range 26-36 
seconds) and corrected to 42.3 seconds 
with the addition of phospholipid, giving a 
normalized DRVVT ratio of 2.6 (normal 
range up to 1.2) (Table 3). The 
hexagonal II phase phosphatidyle-
thanolamine assay (Staclot-LA), showed 
a positive test for LA at 54 seconds (neg-
ative ≤ 8 sec) (Table 4). The diagnosis of 
acquired factor IX inhibitor was therefore 
revised and the prolonged APTT was 
attributed to the presence of a LA. The 
patient underwent a second surgical 
drainage and saucerisation of the ab-
scesses, this time without any factor 
cover. There was no bleeding complica-
tion. Her blood cultures were negative 
but the indirect fluorescent antibody titer 
for meloidosis was positive (1:160). She 
responded to treatment with intravenous 
ceftazidime and oral cotrimoxazole.  She 
has had no recurrence of the abscesses 
and is on long-term treatment with co-
trimoxazole. A repeat test 6 months later 
showed persistence of the LA. 
 
MATERIALS AND METHODS 
 
The PT, APTT and factor assays were 
determined by using an automated coa-
gulation analyzer (ACL 9000, Instrument 
Laboratory, USA). The PT reagents in-
clude fibrinogen HS and calcium throm-
boplastin (Rabbit-brain tissue), the APTT 
reagents consist of phospholipids (syn-
thetic derived for optimal platelet lite ac-
tivity) and calcium chloride (0.020M). All 
these reagents were supplied by the 
company from the Instrument Laboratory 
Sdn. Bhd. Mixing studies were performed 
using pooled plasma from 50 healthy 
normal individuals recruited from our 
hospital. The factor deficient plasma was 
commercially obtained from the Instru-
ment Laboratory (USA). The presence of 
LA was detected by the dilute Russell’s 
viper venom test (DRVVT) and the Staclot 
 
Table 1: Factor assays at serial dilutions. Low 
factor level was observed for all factor assays 
which could due to nonspecific inhibitor. 
 
Dilution Neat 1/5 1/10 1/50 1/100 
Factor 
VIII:C % 22 25 25 <1.0 <1.0 
Factor 
IX:C % <1.0 <1.0 <1.0 <1.0 <1.0 
Factor 
XI:C % <1.0 <1.0 <1.0 <1.0 <1.0 
Factor 
XII:C % <1.0 <1.0 <1.0 <1.0 <1.0 
 
Table 2: Normal Control and Patient’s Plasma for Phospholipid mixing studies 
Factors % 









VIII 88 48 22 82 
IX 97 42 < 1.0 89 
XI 87 42 < 1.0 88 
XII 89 54 < 1.0 89 
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Table 3: Dilute Russell Viper Venom Test 
 
Test  Results (Seconds, sec) 
LA-screen 88.2     Normal range: 31- 42 sec 
LA-confirm 42.3     Normal range: 30 – 37 sec 
Normalized 
ratio 2.6       Normal  ≤ 1.2 
 
 
Table 4: Hexagonal II phase phosphatidylethano-
lamine assay (Staclot-LA)  
    
Test  Results (Seconds, sec) 
Tube 1 (- phospholipid) 123 s 
Tube 2 (+ phospholipid) 69 s 
Correction 54 s (positive >8 sec) 
 
LA. The phospholipid from the Staclot LA 





The activated partial thromboplastin time 
(APTT) is a non-specific screening test of 
the intrinsic system while the prothrombin 
time (PT) is a screening test of the ex-
trinsic system. A prolonged APTT with a 
normal PT indicates a possible deficiency 
of factors VIII, IX, XI or XII or the pres-
ence of inhibitors. These inhibitors are 
either specific to these factors or are non-
specific, the most common of which is 
the lupus anticoagulant (LA) (Chng et al. 
2005). No single test is definitive for a 
LA. As a result, a variety of tests and also 
the clinical history are used in an attempt 
to establish the diagnosis (Lupus anti-
coagulant working party 1991). In the 
present case, a misdiagnosis of factor IX 
inhibitor was made based on the initial 
test showing a low factor IX with normal 
factor VIII levels. The clinical history is 
very important to help us decide what 
further tests need to be done. A specific 
factor inhibitor usually has bleeding ma-
nifestations. In this case the patient had 
no bleeding symptoms, so one should 
suspect the presence of a LA. Lupus an-
ticoagulant can affect the apparent level 
of coagulation factors by interfering with 
the phospholipid-dependent one-stage 
assay based on APTT. In our experience 
factor IX and XI assays are affected mar-
kedly than factor VIII. To overcome this, 
dilution assays on the patient’s plasma 
should have been carried out to dilute out 
the effect of the lupus inhibitor (Kasper 
1991).  
In our laboratory, we found multiple 
factor deficiencies which made it easier 
as we then knew we were most likely 
dealing with a nonspecific inhibitor such 
as a LA. The dilution assays however did 
not show a rise in the apparent factor 
VIII, IX, XI and XII levels as would be ex-
pected in the presence of a LA with factor 
levels remaining low in the presence of a 
specific inhibitor (Kasper 1991). This 
could be explained by the interference of 
a very strong lupus inhibitor. The factor 
VIII level did rise a little but fell to < 1.0% 
at dilutions above 1/50, most likely due to 
dilution of the factor itself. To further 
prove that the apparent low factor levels 
were due to the presence of the LA, we 
added phospholipid to the patient’s 
plasma and repeated the factor assays. 
Addition of phospholipid neutralizes the 
effect of LA and will correct the clotting 
times in the APTT-based factor assays 
(Tripodi 2007). This was clearly shown by 
the normalization of the apparent low 
factor levels with addition of phospholi-
pid. It should be noted that addition of 
phospholipid to normal plasma produces 
a small dilution effect reducing the factor 
level slightly. We also did the chromo-
genic assay for factor VIII and this was 
normal. Chromogenic factor assays are 
based on chromogenic substrates spe-
cific for the factor assayed and are not 
phospholipid-dependent, hence will not 
be affected by the LA (Kazmi et al. 1998). 
The DRVVT and Staclot tests confirmed 
the presence of a LA in our patient. The 
DRVVT is very specific for LA and is not 
prolonged in the presence of a specific 




inhibitor to factor VIII or IX as the DRVVT 
directly activates factor X (Tropodi et al. 
2005). 
This patient was treated initially with re-
combinant activated factor VII when she 
was misdiagnosed with factor IX inhibitor. 
This was unnecessary and inappropriate. 
Not only was it expensive, it could have 
been dangerous to the patient as she 
could have had a thrombosis. Patients 
with LA have an increased risk for throm-
bosis and infusion of activated factor 
concentrates will increase this risk fur-
ther.  This case report illustrates the im-
portance of correct interpretation of factor 
assays in the presence of a LA to avoid 
misdiagnosis and inappropriate treat-
ment.  In summary, a specific factor inhi-
bitor can be differentiated from a lupus 
anticoagulant by: (1) the clinical history: 
patients with a specific factor inhibitor 
usually bleed, while patients with LA are 
usually asymptomatic or they may 
present with a thrombosis; they rarely 
bleed; (2) dilution assays: factor levels 
with a specific inhibitor should not rise 
with serial dilutions of patient’s plasma; 
(3) DRVVT: a specific factor inhibitor to 
factor VIII or IX will not prolong the 
DRVVT; (4) mixing with phospholipids: a 
specific factor inhibitor should not be cor-
rected with phospholipids and (5) chro-
mogenic factor assay: factors assayed by 
the chromogenic method will remain low 
in the presence of a specific factor inhi-




A lupus anticoagulant can affect the ap-
parent levels of the APTT-based factor 
assays leading to a misdiagnosis of a 
specific factor inhibitor. It is important to 
distinguish LA interference from factor 
deficiency or the presence of a specific 
factor inhibitor to avoid misdiagnosis be-
cause the implications and the treatment 
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